Drugs influencing on PCSK9 activity: modelling of efficacy in patients who had myocardial infarction with uncontrolled dyslipidemia
Cardiovascular diseases are the leading cause of death worldwide. It is possible to influence the development of these diseases by influencing their main pathogenetic link - dyslipidemia.Aim: to evaluate, using the example of alirocumab, the potential effect of drugs affecting the activity of PCSK9 on t...
Saved in:
Main Authors: | V. I. Ignatyeva (Author), A. V. Kontsevaya (Author), O. M. Drapkina (Author), E. V. Derkach (Author) |
---|---|
Format: | Book |
Published: |
Izdatelstvo OKI,
2023-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The therapeutic effect of PCSK9 inhibitors on dyslipidemia: one-year follow up
by: Maryam Moshkani Farahani, et al.
Published: (2024) -
Economic Burden of Myocardial Infarction Combined With Dyslipidemia
by: Pingyu Chen, et al.
Published: (2021) -
EFFICACY OF ROSUVASTATIN IN DYSLIPIDEMIA CORRECTION IN PATIENTS AFTER Q-WAVE MYOCARDIAL INFARCTION
by: R. D. Kurbanov, et al.
Published: (2015) -
EFFICACY OF ROSUVASTATIN IN DYSLIPIDEMIA CORRECTION IN PATIENTS AFTER Q-WAVE MYOCARDIAL INFARCTION
by: R. D. Kurbanov, et al.
Published: (2015) -
PCSK9 Inhibitors in Clinical Practice: Experience of a Specialized Lipid Center
by: A. V. Blokhina, et al.
Published: (2022)